Get the Daily Brief
Latest Biotech News
Skye Bioscience’s CB1 Inhibitor Fails in Phase 2 Obesity Trial
Skye Bioscience’s peripherally restricted CB1 receptor inhibitor nimacimab failed to meet the primary endpoint in a 26-week Phase 2a trial for weight loss monotherapy in overweight and obese...
New Genetic Insights in Autoimmune Leukemia Immunotherapy
Researchers at Lund University identified SLAMF6, a surface protein expressed on acute myeloid leukemia (AML) cells that functions as an immune evasion mechanism by suppressing T cell attack....
Sobriety from Toxic Farming Inputs: Plant-Based Seed Lubricants Advance
Researchers have developed new biodegradable, non-toxic solid lubricants derived from cellulose as an environmentally friendly alternative to talc and microplastic lubricants widely used in seed...
Nobel Prize Honors Regulatory T Cell Discoveries in Autoimmunity
The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their seminal work on regulatory T cells (Tregs) and their role in peripheral...
Skye Bioscience Obesity Drug Fails Mid-Stage Trial; Combo Shows Promise
Skye Bioscience announced topline results from its Phase 2a CBeyond trial evaluating nimacimab, a peripherally restricted CB1 inhibitor antibody, for weight loss. As monotherapy, nimacimab failed...
Algen and AstraZeneca Ink $555M AI-Driven Drug Discovery Pact
AstraZeneca and San Francisco-based biotech Algen Biotechnologies announced a collaboration worth up to $555 million to accelerate immunology drug discovery. Algen will apply its AlgenBrain...
Regencell Stock Surges 64,000% Amid Speculative Mania
Regencell Bioscience Holdings, an early-stage biotech focused on Traditional Chinese Medicine treatments for neurodevelopmental disorders, witnessed an unprecedented stock surge of over 64,000% in...
Breakthrough Nanoparticle Therapy Reverses Alzheimer’s Pathology in Mice
Scientists at IBEC and West China Hospital developed a novel bioactive nanoparticle therapy that restores blood-brain barrier (BBB) function, promoting clearance of amyloid-β (Aβ) plaques central...
Aerska Raises $21M to Advance RNAi Therapeutics for Neurological Diseases
Dublin-based biotech Aerska has emerged from stealth mode with $21 million in seed funding to develop antibody-oligonucleotide conjugates (AOCs) designed to deliver RNA interference therapies...
Asimov Launches Stable Producer Cell Lines for Scalable AAV Gene Therapy Manufacturing
Asimov announced its AAV Edge Stable Producer system, generating stable HEK293 cell lines that integrate all necessary viral genes for adeno-associated virus (AAV) production, overcoming...
Discovery of SLAMF6 Protein as Immune Escape Target in Acute Myeloid Leukemia
Researchers at Lund University identified SLAMF6, a surface protein expressed on approximately 60% of acute myeloid leukemia (AML) cases, which acts as an immune-suppressive shield enabling...
FDA Pilot Program to Accelerate Review of Generics Using U.S.-Sourced Ingredients
The FDA has launched a pilot program to speed regulatory review of generic drugs manufactured in the U.S. using domestically sourced active pharmaceutical ingredients (APIs). This initiative aims...
Abivax Shows Additional Positive Data in Phase 3 Ulcerative Colitis Trial
Abivax presented further analyses from its pivotal Phase 3 trial of obefazimod, its lead drug candidate for ulcerative colitis. The pooled data from nearly 1,300 patients reinforce the therapeutic...
Sofinnova’s Strategic Rescue Sparks Abivax’s Phase III Triumph
Sofinnova Partners orchestrated a transformative comeback for French biotech Abivax, beginning with a pivotal €12 million investment in 2019 during the company's financial distress. Recognizing...
AstraZeneca Advances Hypertension and Breast Cancer Treatments
AstraZeneca reported victories on multiple fronts with its blood pressure drug baxdrostat, securing a second successful Phase 3 trial demonstrating efficacy in treatment-resistant hypertension...
Skye Bioscience’s Obesity Drug Stumbles in Phase 2 Trial
Skye Bioscience faced a major setback when its CB1 receptor-blocking antibody nimacimab failed to achieve significant weight loss as monotherapy in a 26-week Phase 2a trial. Despite this,...
AI-Driven Drug Discovery and Biotech Investment Trends Intensify
Artificial intelligence continues to reshape biotech discovery and investment landscapes. Insilico Medicine unveiled its LEGION workflow to comprehensively explore drug-like chemical space while...
Regulatory and Manufacturing Shifts Propel Biopharma Ecosystem Changes
Recent regulatory and manufacturing initiatives signal a pivotal shift in biopharmaceutical industry operations. The FDA launched a pilot program to accelerate generic drug approvals emphasizing...
Nobel Prize Honors Regulatory T Cell Discoveries in Autoimmunity
The 2025 Nobel Prize in Physiology or Medicine was awarded to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for elucidating regulatory T cells (Tregs), a crucial peripheral immune tolerance...
Novel Nanoparticle Therapy Reverses Alzheimer’s Pathology in Mice
Researchers at the Institute for Bioengineering of Catalonia and West China Hospital introduced a bioactive nanoparticle therapy that restores blood-brain barrier function, enabling efficient...